HealthStream Reports Record Q4 Revenue, Strong Non-GAAP Growth, Increases Dividend, and Completes Share Repurchase
HSTM is trading near its 52-week low of $19.5 (8.9% above the low) on elevated volume (2.4× avg).
Summary
HealthStream announced record fourth-quarter revenue and strong non-GAAP profitability, alongside a significant dividend increase, completion of a share repurchase program, and two strategic acquisitions, providing positive guidance for 2026.
Key Events · Earnings and Guidance · HSTM
-
Record Q4 2025 Revenue Achieved
HealthStream reported record quarterly revenue of $79.7 million for the fourth quarter of 2025, representing a 7.4% increase from the prior year.
-
Strong Non-GAAP Profitability and Adjusted EBITDA Growth
Despite a GAAP net income decrease primarily due to a $3.8 million CEO stock gift to employees, non-GAAP net income rose 9.5% in Q4 2025, and Adjusted EBITDA increased 16.4% to $18.8 million.
-
Quarterly Cash Dividend Increased by 12.9%
The Board of Directors declared a quarterly cash dividend of $0.035 per share, marking a significant 12.9% increase over the previous quarter's dividend.
-
Completed Share Repurchase Program
The company completed its $10.0 million share repurchase program in January 2026, having repurchased a total of $30.0 million in common stock during 2025.
Analysis · HSTM · Technology
This 8-K filing details HealthStream's strong financial and strategic performance for Q4 and full-year 2025, alongside positive forward-looking actions. The company reported record quarterly revenue and robust growth in non-GAAP profitability metrics like Adjusted EBITDA, which increased 16.4% in Q4. While GAAP net income saw a decline, this was primarily attributed to a $3.8 million CEO stock gift to employees, a unique event demonstrating strong internal alignment and employee retention efforts, rather than operational weakness. Strategically, HealthStream completed two significant acquisitions, Virsys12 and MissionCare Collective, which are expected to expand its healthcare technology platform and market reach. The company also demonstrated a commitment to shareholder returns by completing a $10.0 million share repurchase program in early 2026, part of a larger $30.0 million repurchase effort in 2025. Further reinforcing shareholder value, the Board increased the quarterly cash dividend by a notable 12.9%. The provided 2026 guidance offers a positive outlook for continued growth. Investors should view this comprehensive report as a strong signal of operational health, strategic expansion, and shareholder-friendly capital allocation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSTM was trading at $21.24 on NASDAQ in the Technology sector, with a market capitalization of approximately $630.2M. The 52-week trading range was $19.50 to $34.13. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.